This is the fourth article in a six-part series exploring critical themes shaping the future of functional mushrooms, in partnership with Finnish biotech company KÄÄPÄ Biotech . For centuries, chaga has been one of nature’s most powerful secrets. In the Nordics, in the cold, on slow-growing birch forests, this charcoal-black conk develops over many years. Throughout that time it accumulates the bioactive compounds that have made it an essential part of traditional medicine ac

Too long to read? Go for the highlights below. Finnish biotechnology firm Kääpä Biotech  has closed a €9 million strategic investment led by PeakBridge and Zintinus to expand production capacity and strengthen its position in the global nutraceutical market The funding will enable vertical integration expansion and scale operations to meet surging international demand from over 180 companies across 20+ markets This marks PeakBridge's second investment in Kääpä following a €90

This is the second article in a six-part series exploring critical themes shaping the future of functional mushrooms, in partnership with Finnish biotech company KÄÄPÄ Biotech . In the evolving landscape of the functional mushroom industry, transparency has emerged as a cornerstone of consumer trust, product integrity, and scientific credibility. As the functional mushroom market rapidly grows ( see the first article in this series by KÄÄPÄ Biotech ), together with the trendi

White Paper, Beyond Beta-Glucans, builds on years of scientific development to propose a compelling, evidence-based rethink. It’s time the industry moves beyond beta-glucan content as the default quality metric.

Researchers examined four wild mushroom species from Kargil and found them packed with essential nutrients, antioxidants, and bioactive compounds, positioning them as promising candidates for dietary supplements and functional foods.